Tamer H. Mahmoud

Tamer H. Mahmoud

Auto-generated profile, based on publicly available information

Tamer H. Mahmoud

Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in JAMA Ophthalmology
Verified
Journal Article
Closed access
PDF file
DGDilraj S. Grewal
Dilraj S. Grewal
TMTamer H. Mahmoud
Tamer H. Mahmoud
Review from JAMA Ophthalmology — Autologous Neurosensory Retinal Free Flap for Closure of Refractory Myopic Macular Holes

1 October 2014 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
GYGlenn Yiu
Glenn Yiu
VMVarsha Manjunath
Varsha Manjunath
SCStephanie J. Chiu
Stephanie J. Chiu
SFSina Farsiu
Sina Farsiu
TMTamer H. Mahmoud
Tamer H. Mahmoud

1 April 2015 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
PHPaul Hahn
Paul Hahn
MCMina M. Chung
Mina M. Chung
HFHarry W. Flynn
Harry W. Flynn
SHSuber S. Huang
Suber S. Huang
JKJudy E. Kim
Judy E. Kim
PDPravin U. Dugel
Pravin U. Dugel
The American Society of Retina Specialists (ASRS) Therapeutic Surveillance Subcommittee (TSC) serves as an independent task force to objectively monitor drug- and device-related adverse events on behalf of the greater community of retina specialists and their patients. The ASRS TSC has maintained a history of prompt investigation of adverse events, including identification of a fungal endophthalmitis outbreak related to improperly compounded Brilliant Blue G in a single responsible pharmacy,1 which was subsequently closed, and comprehensive classification and analysis of postmarketing adverse events reported after ocriplasmin (Jetrea; ThromboGenics Inc) administration. Within the first 3 months of aflibercept use (Eylea; Regeneron Pharmaceuticals Inc) after approval by the Food and Drug Administration (FDA) in November 2011, a cluster of aflibercept-related sterile intraocular inflammation was similarly reported. The ASRS TSC received reports of 15 cases in those 3 months, surveyed the reporting physicians for detailed information surrounding these events, and reported findings of sterile inflammation not associated with any identifiable causative factors.2 Of note, 47% of those cases were successfully treated with a return to baseline vision with topical corticosteroids alone, demonstrating that invasive interventions, including vitreous biopsy and intravitreal antibiotic administration or vitrectomy, may be avoided in select circumstances. Subsequent cases of sterile inflammation after aflibercept have continued to be submitted to the TSC. This report serves to describe these events and to analyze these data for any associated factors, consistent with the mission of the TSC to investigate and inform the ophthalmology community regarding drug- and device-related safety events.

1 May 2013 in Ophthalmology
Verified
Journal Article
Open access
PHPaul Hahn
Paul Hahn
JKJudy E. Kim
Judy E. Kim
SSSandra Stinnett
Sandra Stinnett
MCMina M. Chung
Mina M. Chung
PDPravin U. Dugel
Pravin U. Dugel
TMTamer H. Mahmoud
Tamer H. Mahmoud

1 December 2013 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
JMJoseph N. Martel
Joseph N. Martel
TMTamer H. Mahmoud
Tamer H. Mahmoud
Massive submacular hemorrhage can cause disastrous visual complications. Prompt displacement away from the fovea is desirable in some patients. We describe a novel surgical technique involving subretinal air as a therapeutic adjuvant for massive submacular hemorrhage displacement.

1 November 2011 in Retina
Verified
Journal Article
Closed access
JBJamin S Brown
Jamin S Brown
TMTamer H Mahmoud
Tamer H Mahmoud
The purpose of this study was to provide further information about the risks of perioperative hemorrhage in diabetic vitrectomy in patients on anticoagulation. This may help us to better understand more about the fine balance between the risks of stopping anticoagulation versus continuation for intraocular surgery. A retrospective, comparative cohort study of all patients undergoing a diabetic pars plana vitrectomy by a single surgeon over a 30-month period at a single institution was conducted. Ninety-seven eyes were included for analysis. Twenty-seven eyes remained on anticoagulation during the surgery. There were no perioperative complications related to the anticoagulation. Surgical intervention resulted in a significant increase in visual acuity in both groups. There was no difference in the incidence of postoperative vitreous hemorrhage or surgical reoperation between the two groups. Patients on anticoagulation had significantly worse postoperative vision compared with those not on anticoagulation (best-corrected visual acuity of 20/230 vs. 20/100, P = 0.03). Patients undergoing diabetic vitrectomy, who are on anticoagulation or antiplatelet agents, do not exhibit a higher risk of intraoperative or postoperative vitreous hemorrhage. Anticoagulants and antiplatelets may be safely continued perioperatively to avoid complications secondary to their systemic disease.